Domestic orphan drug giant joins hands with Pfizer to jointly develop breast cancer treatment

Breast cancer is a major killer of women’s health.
According to data from the World Health Organization, there are 2.
26 million new cases of breast cancer worldwide in 2020, surpassing the 2.
2 million cases of lung cancer
.
The number of breast cancer patients in China is huge, and there are about 400,000 new breast cancer patients every year
.
Among all breast cancer patients, HER-2 positive patients account for about 20-30%
.
HER2-positive breast cancer is an abnormally dangerous breast cancer.
Its tumor cells are more malignant, the disease progresses faster, metastasis and recurrence are more likely to occur, and the prognosis is poor
.
In recent years, with the continuous development of medical technology and technology, the emergence of anti-HER-2 treatments has brought new hope to patients
.
At present, there are endless new anti-HER2 drugs on the market, but due to the huge base of breast cancer patients in China, there is still a huge gap between patient demand and drug availability
.
The domestic orphan drug giant Yasheng Pharmaceutical announced on the evening of November 8 that the company and Pfizer have reached a clinical cooperation and drug supply agreement.
According to the terms of the agreement, Yasheng Pharmaceutical will be responsible for carrying out the research, and Pfizer will be responsible for providing the drugs needed for the research.
Research new options for the treatment of breast cancer
.
Specifically, the two parties will jointly develop Lisaftoclax (APG-2575), a selective Bcl-2 inhibitor of Ascent Pharmaceuticals, combined with Pfizer's CDK4/6 inhibitor, Aiboxin (pibacillil), for the treatment of relapsed and locally advanced stages.
Or metastatic estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer treatment
.
It is understood that APG-2575 is an important product of Ascent Pharmaceutical’s apoptosis pipeline.
It restores the programmed cell death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby killing tumors, and is useful for the treatment of a variety of blood Tumors and refractory solid tumors have great clinical potential
.
APG-2575 is also the first locally developed Bcl-2 selective inhibitor, and its two indications (WM, chronic lymphocytic leukemia) have obtained orphan drug designation granted by the US FDA
.
The partnership between the company and Pfizer will help accelerate the clinical development of the product
.
Piperacillil is a blockbuster product developed by Pfizer for the treatment of breast cancer, which can significantly prolong the progression-free survival of patients with advanced breast cancer and provide new treatment options for patients with advanced breast cancer
.
In 2018, the import of piperacillil capsules was approved by the NMPA for use in locally advanced or metastatic breast cancer with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative.
It should be combined with aromatase inhibitors Used as the initial endocrine therapy for postmenopausal female patients
.
The drug's sales in 2020 were 5.
39 billion U.
S.
dollars, a year-on-year increase of 9%
.
However, in the first quarter of 2021, sales of the product fell by 7%, and Pfizer attributed the decline to COVID-19-related economic difficulties that increased the number of registrations for the drug's patient assistance program
.
Ascent Pharmaceuticals hopes that APG-2575 combined with piperacillil will show a synergistic effect in the treatment of metastatic breast cancer that is resistant to the CDK4/6 inhibitor piperacillil, bringing hope to patients around the world who are in desperate need of new treatment options
.
Prior to this, Yasheng Pharmaceutical has simultaneously promoted the clinical development of APG-2575 for the treatment of various hematological tumors in the United States, Europe, China and Australia
.
According to the data, Yasheng Pharmaceutical is an original innovative drug research and development company based in China and facing the world in the clinical development stage.
It is committed to the development of innovative drugs in the treatment of tumors, hepatitis B and aging-related diseases
.
The company has established a pipeline of 8 Class 1 small molecule new drug products that have entered the clinical development stage.
Up to now, the company has 4 new drugs under development that have obtained 12 FDA orphan drug certifications. .
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"32"},"share":{},"image":{"viewList":["weixin","sqq","qzone","tsina","tqq"," tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:", "viewSize":"24"},"selectShare":{"bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu",